When compared to the 15C18 12 months old girls receiving three doses of the vaccine (standard of care), the L1 antibody titres in the 15C18 12 months old girls receiving two doses were non-inferior for all four HPV types at all time points. age three-dose recipients for all those except HPV 18. The titres were inferior to those in the 10C14 12 months aged three-dose recipients for all those targeted types. Frequency of incident infections from vaccine-targeted HPV types in the 15C18 12 months aged two-dose recipients was similar to the three dose recipients. None of the girls receiving two or three doses had persistent contamination from vaccine-targeted types. These findings support that two doses of HPV vaccine can be extended to girls aged 15C18 years. strong class=”kwd-title” Keywords: Human papillomavirus, Quadrivalent vaccine, Two doses, age 15C18 years, Immunogenicity, Incident infections, Persistent infections 1.?Introduction The knowledge that persistent contamination with a high-risk human papillomavirus (HPV) is the necessary cause of cervical cancer [1], [2] led to the development of prophylactic HPV vaccines. The proportion of Cetilistat (ATL-962) cervical cancers attributed to HPV 16 and 18 ranges from 68% to 82% globally [3], [4] and the first generation of vaccines targeted these two types in a bivalent or quadrivalent format, made up of recombinant virus-like particles (VLP) assembled from the L1 capsid proteins of HPV 16 and 18 or HPV 6, 11, 16 and 18 respectively. Either of these vaccines is used in the national immunization programs of more than 70 countries, although a nonavalent vaccine is now available [5]. Vaccine efficacy of three doses against high-grade cervical intraepithelial neoplasia (CIN) caused by vaccine-targeted HPV was close to Rabbit Polyclonal to Connexin 43 100% in HPV-naive populations and exceeded 55% in intention-to-treat populations [6], [7], [8]. The World Health Organisation (WHO) accepted in the year 2014 that two doses administered at six months interval were sufficient for healthy pre-adolescents aged less than 15 years at the time of the first dose [9], [10]. The high immune response among pre-adolescents indicates the potential of reduced doses in preventing cervical neoplasia [11], [12]. In 2009 2009, the International Agency for Research on Cancer (IARC) initiated a cluster-randomized trial in India to evaluate the effectiveness of two doses of quadrivalent vaccine (Gardasil?, Merck) in preventing cervical neoplasia compared to three doses [13]. The vaccination was suspended prematurely due to reasons unrelated to our study. As a result the study lost its randomized nature and became an observational cohort study with participants having received a single dose, two doses or Cetilistat (ATL-962) three doses of the vaccine. In this manuscript, we compare the immunogenicity outcomes of L1 binding antibody titres, neutralizing antibody titres and antibody avidity against HPV16, HPV18, HPV6 and HPV11 in cohorts of girls aged 15C18 years receiving two doses of the vaccine with the 15C18 12 months old three dose recipients (standard of care) and the 10C14 12 months old three dose recipients (best response group) in order to determine whether the benefit of the reduced dose regime can be extended to older girls as well. This immunogenicity analysis was based on participants in the trial who were randomly recruited prior to the break in enrollment, and that this represents 52.6% of the entire cohort. We have also reported the frequency of incident and persistent HPV infections in the different age and dose cohorts as the early efficacy end points. 2.?Methods 2.1. Study design and participants The study design, methods, and study participants characteristics have been described previously [13]. Briefly, the primary objective of the cluster randomized trial initiated at nine locations in India was to evaluate whether two doses of the quadrivalent HPV vaccine administered on days Cetilistat (ATL-962) 1 and 180 would be effective in inducing non-inferior immune response and in Cetilistat (ATL-962) preventing persistent vaccine-targeted HPV contamination and cervical neoplasia compared to three doses administered on days 1, 60 and 180. The study recruited unmarried girls who were between 10 and 18 years of age on the date of recruitment. The ethical review committees of the participating centres and IARC approved the study. Written informed consent was obtained from one of the parents, or legal guardian, along with the assent of the participating lady. At follow-up, a fresh consent was obtained from the girls when they completed 18 years of age. A data safety monitoring board was constituted to regularly monitor the safety and outcomes of the study. The study Cetilistat (ATL-962) is usually registered as Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India with ISRCTN (registration number.
Categories